Search Results

ML327 5 mg  | 99.48%

TargetMol

ML327 is a MYC blocker. ML327 can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).

More Information Supplier Page

ML327 10 mg  | 99.48%

TargetMol

ML327 is a MYC blocker. ML327 can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).

More Information Supplier Page

Cefquinome sulfate 100 mg  | Purity Not Available

TargetMol

Cefquinome Sulfate is a semisynthetic, broad-spectrum, fourth-generation aminothiazolyl cephalosporin with antibacterial activity.

More Information Supplier Page

Cefquinome sulfate 200 mg  | Purity Not Available

TargetMol

Cefquinome Sulfate is a semisynthetic, broad-spectrum, fourth-generation aminothiazolyl cephalosporin with antibacterial activity.

More Information Supplier Page

AM966 2 mg  | 99.49%

TargetMol

AM966, a excellent affinity, specific, oral LPA1(IC50=17 nM) antagonist, suppresses LPA-stimulated intracellular calcium release.

More Information Supplier Page

AM966 5 mg  | 99.49%

TargetMol

AM966, a excellent affinity, specific, oral LPA1(IC50=17 nM) antagonist, suppresses LPA-stimulated intracellular calcium release.

More Information Supplier Page

AM966 10 mg  | 99.49%

TargetMol

AM966, a excellent affinity, specific, oral LPA1(IC50=17 nM) antagonist, suppresses LPA-stimulated intracellular calcium release.

More Information Supplier Page

AM966 50 mg  | 99.49%

TargetMol

AM966, a excellent affinity, specific, oral LPA1(IC50=17 nM) antagonist, suppresses LPA-stimulated intracellular calcium release.

More Information Supplier Page

AM966 100 mg  | 99.49%

TargetMol

AM966, a excellent affinity, specific, oral LPA1(IC50=17 nM) antagonist, suppresses LPA-stimulated intracellular calcium release.

More Information Supplier Page